SOHM, Inc. Announces Allowances Of Japanese Patent Claims Received from Japan's Patent Office (特許庁, Tokkyochō, JPO) Protecting Transformative SOHM-ABBIE Genome Edited, SAGE Recombinant-Organisms, -Cells, -Secretomes, -Exosomes
Rhea-AI Summary
SOHM Inc (OTC PINK:SHMN) has received a patent allowance from Japan's Patent Office for its ABBIE Genome Editing technology. The patent (No. 2023-121860) protects SOHM's innovative SAGE (SOHM-ABBIE Genome Editing) products and services, which enable precise DNA alterations without causing double-stranded breaks. This technology advancement positions SOHM competitively in the global Cell Therapy market, valued at $4.5 Billion in 2023 and projected to reach $97 Billion by 2033. The company plans to expand its presence in Japan, Korea, China, EU, and other global markets through product sales, services, and strategic partnerships.
Positive
- Secured strategic patent allowance in Japan for ABBIE Genome Editing technology
- Technology enables safer and more precise DNA alterations compared to existing methods
- Entering Cell Therapy market valued at $4.5B with projected growth to $97B by 2033
- Potential for revenue generation through licensing, R&D kit sales, and strategic partnerships
Negative
- None.
News Market Reaction
On the day this news was published, SHMN declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
For Pharmaceutical, Nutraceutical, Cosmeceutical & Strategic Partnered Products
CHINO HILLS, CA / ACCESSWIRE / November 14, 2024 / SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs, has announced today receipt of the Official Notice Of Patent Allowance from Japan's Patent Office (特許庁Tokkyochō, JPO). SOHM Inc's Japanese Patent No. 2023-121860 is entitled, "CAS 9 RETROVIRAL INTEGRASE AND CAS 9 RECOMBINASE SYSTEMS FOR TARGETED INCORPORATION OF A DNA SEQUENCE INTO A GENOME OF A CELL OR ORGANISM," protecting SOHM's innovative and bio-validated ABBIE (ABase Binding Integrase Enzyme) Genome Editing products and services.
SOHM ABBIE Genome Editing (SAGE) refers to proprietary gene editing, paradigm-changing, revolutionary-new, advanced-methods for safe-effective, specifically targeted, desired alterations of endogenous cell or organism genomic DNA sequences by inserting exogenous DNA sequences into the cell's genomic DNA sequences. SOHM-ABBIE Genome Editing, branded as SAGE, enables transformative precision Biotechnology proprietary products and services in pioneering advances in manufacturing of highly precise, targeted, rapid, efficacious, safe, transformative genome edited recombinant bioproducts. The Japan patent is a significant milestone for SOHM Inc, as it expands the Company's International Intellectual Property Portfolio into highly competitive, dynamically growing, multi-billion dollar global-markets for SOHM ABBIE Genome Edited-SAGE products and services. SOHM, Inc. manufactures, markets and sells SAGE-Synthetic Biology R&D Kits, cell engineering services and high-throughput rapid drug screening assays via engineered cell lines
In summary, SOHM's new ABBIE patent allowance in Japan allows further out-licensing of SOHM, Inc.'s SAGE-IP, as well as furthering SAGE R&D Kit sales opportunities, enabling generation of novel proprietary ABBIE recombinant human and animal medical therapeutics, microbial and plant cell recombinant SAGE BioTechnologies, Synthetic Biologics, and Precision Medicines; including recombinant product commercial development. SOHM plans to significantly strengthen their competitive biotechnology position relative to CRISPR. Marketing and Sales of SAGE -products, -services, -out-licenses and -strategic partnering's will continue to be added in Japan, Korea, China, EU and other Global and American markets.
The Cell Therapy global market was valued at
"The SOHM-ABBIE teams are fully dedicated to fully enabling and providing precision delivery of large payloads of DNA, without inducing any double-stranded genomic DNA break(s) leading to toxic events, observed by other Genome-Editing BioTechnologies" said SOHM COO, David C. Aguilar PhD. David added, "the IP development of CAS 9 RETROVIRAL INTEGRASE AND CAS 9 RECOMBINASE SYSTEMS FOR TARGETED INCORPORATION OF A DNA SEQUENCE INTO A GENOME OF A CELL OR ORGANISM," not only enhances our Intellectual Property strategy and growing Patent Portfolio, but also opens up new opportunities for collaborative new products and expansion within Japan, Korea, China, Indo-Asiatic, Pacific Rim and markets in the Americas. The biotechnology covered by the Japanese patent allowance is expected to facilitate the development of transformative therapies leading to possible longer-term remissions and complete tumor regressions for cancer and potential cures for other congenital or acquired diseases and conditions."
For further information regarding this announcement or to explore potential SOHM SAGE collaborations, please contact us.
About SOHM, Inc.:
SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy.
To learn more about SOHM, Inc., visit www.SOHM.com.
SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: info@sohm.com
Phone: (714) 522-6700
Safe Harbor Statement:
This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
SOURCE: SOHM, Inc
View the original press release on accesswire.com
FAQ
What is the significance of SOHM's (SHMN) new Japanese patent allowance?
How does SOHM's (SHMN) SAGE technology differ from other genome editing methods?
What is the market potential for SOHM's (SHMN) cell therapy technology?
